Menu
Home
Products
Specialties
Events
Services
Contact Janssen
Login
Choose your language
Menu
Products
Specialties
Events
Services
Contact Janssen
Choose your language
Tremfya-Pso/PsA mode of Action
Services
Media Center
It seems your browser is blocking 3rd party cookies which are required to display videos. To resolve this issue, please update your cookie settings to allow these 3rd party cookies.
Manage cookie settings
Tremfya
®
is the first biologic indicated for the management of PsA, fully human monoclonal antibody (mAb) that selectively targets IL‑231-3